SCHEMBL2851318

SCHEMBL2851318

C=C(C#N)C(O)c1cc(C(=O)OCC)c(-c2ccccc2)nc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.52
ALDH1A1 P00352 10/20 0.52
L3MBTL1 Q9Y468 9/20 0.52
TDP1 Q9NUW8 6/20 0.52
HTT P42858 3/20 0.51
GPR55 Q9Y2T6 2/20 0.51
LMNA P02545 5/20 0.50
HPGD P15428 4/20 0.50
NPSR1 Q6W5P4 3/20 0.49
CYP1A2 P05177 3/20 0.48
CYP2C9 P11712 3/20 0.48
CYP2C19 P33261 3/20 0.48
CYP3A4 P08684 2/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 1/20 0.46
ATM Q13315 1/20 0.46
ADORA3 P0DMS8 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853071 0.86 CASP1 (0.55) KDM4EALDH1A1L3MBTL1TDP1HTT
SCHEMBL2858064 0.85 CASP1 (0.36) KDM4EALDH1A1L3MBTL1TDP1HTT
SCHEMBL2853119 0.84 CASP1 (0.47) KDM4EALDH1A1L3MBTL1TDP1HTT
SCHEMBL2853211 0.81 L3MBTL1 (0.39) KDM4EALDH1A1L3MBTL1LMNAHPGD
SCHEMBL13500074 0.79 SQOR (0.33) KDM4EALDH1A1L3MBTL1TDP1HTT
SCHEMBL2849135 0.78 CASP1 (0.56) KDM4EALDH1A1L3MBTL1TDP1HTT
SCHEMBL4793182 0.75 ALDH1A1 (0.46) KDM4EALDH1A1L3MBTL1TDP1HTT
SCHEMBL2853271 0.74 ALDH1A1 (0.43) KDM4EALDH1A1L3MBTL1TDP1HTT
SCHEMBL2851268 0.74 CASP1 (0.58) ALDH1A1LMNACYP1A2CYP2C9CYP2C19
SCHEMBL30040702 0.74 ALDH1A1 (0.68) KDM4EALDH1A1L3MBTL1TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US claimed
EP-1924558-B1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2010-01-13 EP claimed
EP-1924558-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-05-28 EP claimed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US claimed
WO-2007032016-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-03-22 WO claimed
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US disclosed
US-7666883-B2 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-23 US disclosed
EP-1924558-B1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2010-01-13 EP disclosed
EP-1924558-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-05-28 EP disclosed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US disclosed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US disclosed
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-05-24 US disclosed
WO-2007032016-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117822-A1 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof HBS1L, SSBP1, QARS1 KDM4E 524/4885ALDH1A1 1459/4885L3MBTL1 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.